Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 13/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936191 | 0.89 | KMT2A (0.45) | USP2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL2236993 | 0.84 | USP2 (0.43) | USP2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL937908 | 0.84 | MEN1 (0.48) | USP2MAPTKMT2AMEN1BDKRB1 | |
| SCHEMBL3230489 | 0.83 | MAPK1 (0.46) | MAPTKMT2AALDH1A1BDKRB1 | |
| SCHEMBL1936190 | 0.83 | MEN1 (0.45) | USP2MAPTKMT2AMEN1BDKRB1 | |
| SCHEMBL1936194 | 0.81 | MEN1 (0.42) | USP2MAPTKMT2AMEN1BDKRB1 | |
| SCHEMBL938115 | 0.78 | MEN1 (0.51) | USP2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL2236591 | 0.77 | MEN1 (0.41) | USP2MAPTKMT2AMEN1BDKRB1 | |
| SCHEMBL1936197 | 0.76 | MEN1 (0.46) | USP2MAPTKMT2AMEN1BDKRB1 | |
| SCHEMBL2205403 | 0.75 | BDKRB1 (0.47) | KMT2AMEN1BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | USP2 4171/4885MAPT 2733/4885KMT2A 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.